drugset / Trial / NCT04392271

A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants

NCT04392271 ↗

Phase 1 Completed 4 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to about 10 weeks. Screening must be completed within four weeks prior to enrollment.

Timeline

Start
2020-08-06
Primary completion
2020-10-14
Completion
2020-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ceperognastat Small molecule — Oral

Indications

No indication recorded.